CDH17 and neoplasm: In this study, we engineered the non‐pathogenic bacteria MG1655 by introducing CDH17 nanobodies onto their surface through fusion with the C‐terminal fragment of EHEC intimin to enhance bacterial targeting efficiency to tumors.[17] Our data demonstrated that, in three tumor models, MG1655 engineered with Nb289 could rapidly and abundantly home to CDH17‐positive tumors, at least 24 h earlier than unmodified MG1655.